Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.

When combining sacituzumab govitecan (SASE) and pembrolizumab (IO), it's crucial to differentiate the cause of diarrhea. SASE-induced diarrhea is similar to standard chemotherapy, while IO-induced diarrhea often presents with bloody stools and severe abdominal cramping.

Despite targeting the same protein (Trope-2), different ADCs like sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) exhibit unique toxicity profiles due to their different linker-payloads. Clinicians must be prepared for diarrhea with SG versus oral mucositis with sac-TMT, requiring distinct mitigation strategies for drugs that otherwise seem very similar.

The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.

Though ADCs like Sacituzumab Govitekan cause notable side effects like diarrhea and neutropenia, patient-reported outcome data shows they provide a meaningful and sustained improvement in quality of life compared to standard chemotherapy. This was observed even with longer treatment durations and lower discontinuation rates.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

Managing side effects of antibody-drug conjugates is not one-size-fits-all. Sazetuzumab-govatecan requires managing GI issues, while Datopotamab-deruxtecan has unique risks like ophthalmologic problems and ILD, necessitating pre-treatment specialist evaluation. Proactive patient education and tailored mitigation are key to maintaining treatment continuity and efficacy.

To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.

Severe nausea from the Claudin-18.2 antibody zolbetuximab dropped from ~20% in early trials to zero in a recent study. This was achieved not by changing the drug, but by clinicians learning and applying more effective proactive antiemetic strategies, demonstrating the power of evolving supportive care.